TransMedics Group, Inc. logo
TransMedics Group, Inc. (TMDX)
Compare

TransMedics Group, Inc. (TMDX) Average EV/EBIT Ratio

EV/EBIT Ratio

The current ev/ebit ratio for TransMedics Group, Inc. (TMDX) is 34.45x as of Saturday, June 20, 2026, shown against its trailing averages.

Average EV/EBIT Ratio Chart

TMDX EV/EBIT Ratio Averages

EV/EBIT RATIO CURRENT

34.45x

EV/EBIT RATIO TTM

56.95x

EV/EBIT RATIO 3Y

68.54x

EV/EBIT RATIO 5Y

68.54x

EV/EBIT RATIO 10Y

68.54x

EV/EBIT RATIO 15Y

68.54x

EV/EBIT RATIO 20Y

68.54x

About TransMedics Group, Inc.

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

Andover, MA
728 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Waleed H. Hassanein